Marimastat (BB2516): current status of development.

abstract：PURPOSE:The activity of 5-fluorouracil (5-FU) against colon cancer is enhanced by leucovorin and the combination of 5-FU and levamisole has activity in the adjuvant treatment of colonic malignancies. The combination of 5-FU with both leucovorin and levamisole may provide additional benefit in the treatment of colon can...

journal_title：Cancer chemotherapy and pharmacology

authors： Cleary JF,Arzoomanian R,Alberti D,Feierabend C,Storer B,Witt P,Carbone P,Wilding G

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:Paclitaxel-based chemoradiotherapy was proven to be efficacious in treating patients with advanced esophageal cancer. However, the toxicity and the development of resistance limited its anticancer efficiency. The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both...

journal_title：Cancer chemotherapy and pharmacology

authors： Guo XF,Li SS,Zhu XF,Dou QH,Liu D

更新日期：2018-09-01 00:00:00

abstract：PURPOSE:The present study was designed to determine pharmacological and biochemical properties of 2-methoxyantimycin A analogs (OMe-A1, OMe-A2, OMe-A3, and OMe-A5), which are novel antitumor compounds, and provide a basis for future pharmaceutical development, preclinical evaluation, and clinical trials. METHODS:A hig...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang H,Li M,Rhie JK,Hockenbery DM,Covey JM,Zhang R,Hill DL

更新日期：2005-09-01 00:00:00

abstract：PURPOSE:Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs. METHODS:Tumors were graded according to the World Health Organization 2010 classification system....

journal_title：Cancer chemotherapy and pharmacology

authors： Lee KJ,Cho JH,Lee SH,Song SY,Lee KH,Jeong S,Ryu JK,Woo SM,Bang S,Lee JK,Lee TH,Paik WH,Kim YT,Lee WJ

更新日期：2017-10-01 00:00:00

abstract：BACKGROUND:3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum tolerated dose (MTD) and oral bioavailability of 3-AP in patients with advanced-stage solid tumors. METHODS:Twenty patients received one dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Chao J,Synold TW,Morgan RJ Jr,Kunos C,Longmate J,Lenz HJ,Lim D,Shibata S,Chung V,Stoller RG,Belani CP,Gandara DR,McNamara M,Gitlitz BJ,Lau DH,Ramalingam SS,Davies A,Espinoza-Delgado I,Newman EM,Yen Y

更新日期：2012-03-01 00:00:00

abstract：PURPOSE:Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug monitoring in a 2-week-old neonate with localized hepatoblastoma. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Thomas F,Veal GJ,El Balkhi S,Lafont T,Picard N,Brugières L,Chatelut E,Piguet C

更新日期：2018-08-01 00:00:00

abstract：:All-trans-retinoic acid (ATRA) has been incorporated in front-line therapy for newly diagnosed acute promyelocytic leukemia (APL). We conducted a multicenter study of differentiation therapy with ATRA alone or in combination with chemotherapy followed by intensive postremission chemotherapy in patients with APL (the J...

journal_title：Cancer chemotherapy and pharmacology

authors： Asou N,Adachi K,Tamura U,Kanamaru A,Kageyama S,Hiraoka A,Omoto E,Akiyama H,Tsubaki K,Saito K,Kuriyama K,Oh H,Kitano K,Miyawaki S,Takeyama U,Yamada O,Nishikawa K,Takahashi M,Matsuda S,Ohtake H,Ohno R

更新日期：2001-08-01 00:00:00

abstract：PURPOSE:This exploratory phase II clinical trial evaluated the antitumor activity, safety profile and pharmacokinetics of PM00104 (Zalypsis(®)) 3 mg/m(2) 1 h every 3-week intravenous infusion in patients with advanced and/or metastatic urothelial carcinoma progressing after first-line platinum-based chemotherapy. METH...

journal_title：Cancer chemotherapy and pharmacology

authors： Castellano DE,Bellmunt J,Maroto JP,Font-Pous A,Morales-Barrera R,Ghanem I,Suarez C,Martín Lorente C,Etxaniz O,Capdevila L,Coronado C,Alfaro V,Siguero M,Fernández-Teruel C,Carles J

更新日期：2014-04-01 00:00:00

abstract：PURPOSE:Radiotherapy (RTx) has been considered as the treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). However, with only conventional fractionation (Cfx), response rates are relatively low. In this study, we report the results of hyperfractionation (Hfx) RTx with concurrent docetaxe...

journal_title：Cancer chemotherapy and pharmacology

authors： Katori H,Tsukuda M,Watai K

更新日期：2007-08-01 00:00:00

abstract：PURPOSE:The study investigated the effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells. METHODS:Six human colorectal cancer cells were exposed to pemetrexed, gefitinib, and their combination. Antitumor effects were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium br...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang G,Xie X,Liu T,Yang J,Jiao S

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND:Very little is known about the pharmacokinetics of chemotherapeutic agents in patients also being treated with continuous ambulatory peritoneal dialysis. We sought to evaluate the pharmacokinetics of cisplatin and 5-fluorouracil in plasma and peritoneal dialysate in a patient being treated for esophageal ade...

journal_title：Cancer chemotherapy and pharmacology

authors： Eads JR,Beumer JH,Negrea L,Holleran JL,Strychor S,Meropol NJ

更新日期：2016-02-01 00:00:00

abstract：:Brain microdialysis was applied to sample free methotrexate (MTX) concentrations in brain extracellular fluid of normal and RG-2 glioma-bearing rats. All animals received 50 mg/kg of MTX intra-arterially following which serial blood and interstitial fluid samples were collected for 3 h and measured for MTX by an HPLC ...

journal_title：Cancer chemotherapy and pharmacology

authors： Devineni D,Klein-Szanto A,Gallo JM

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:We conducted phase I and tolerability studies to determine the maximum tolerated dose (MTD) and recommended dose of nab-paclitaxel when administered weekly with solid tumors and to evaluate the tolerability of weekly administration at a dose of 150 mg/m(2) with metastatic breast cancer (MBC) as a first-line the...

journal_title：Cancer chemotherapy and pharmacology

authors： Ando M,Yonemori K,Katsumata N,Shimizu C,Hirata T,Yamamoto H,Hashimoto K,Yunokawa M,Tamura K,Fujiwara Y

更新日期：2012-02-01 00:00:00

abstract：PURPOSE:We examined the interaction between cyclophosphamide (CPA) and angiostatin (AS) on the growth of primary Lewis lung carcinoma (LLC) tumors and on the development of LLC pulmonary metastases. We studied the effects of AS and CPA on the stages of angiogenesis employing in vitro assays. METHODS:Primary tumor grow...

journal_title：Cancer chemotherapy and pharmacology

authors： Mauceri HJ,Seetharam S,Beckett MA,Schumm LP,Koons A,Gupta VK,Park JO,Manan A,Lee JY,Montag AG,Kufe DW,Weichselbaum RR

更新日期：2002-11-01 00:00:00

abstract：PURPOSE:Evodiamine is one of active alkaloids isolated from the traditional Chinese medicine Evodia rutaecarpa Bentham and has various pharmacological properties. In this study, we investigated its effects on the migration, invasion, and associated mechanism in human nasopharyngeal carcinoma (NPC) cells. METHODS:Cell ...

journal_title：Cancer chemotherapy and pharmacology

authors： Peng X,Zhang Q,Zeng Y,Li J,Wang L,Ai P

更新日期：2015-12-01 00:00:00

abstract：PURPOSE:In order to determine the sensitivity and specificity of the test and to optimize experimental conditions utilizing the SBT in a rat model of chemotherapy-induced small intestinal damage. METHODS:Initially, a 13C-sucrose dose-response study was performed in rats to determine an optimal sucrose concentration fo...

journal_title：Cancer chemotherapy and pharmacology

authors： Tooley KL,Howarth GS,Lymn KA,Butler RN

更新日期：2010-04-01 00:00:00

abstract：:Methotrexate and methotrexate polyglutamates were quantitatively determined in red blood cells from 12 children with acute lymphoblastic leukemia who were treated with MTX (15-20 mg/m2 per week) and daily 6-mercaptopurine orally during the steady-state period of erythrocyte MTX concentration (ery-MTX). The terminal de...

journal_title：Cancer chemotherapy and pharmacology

authors： Schrøder H,Fogh K

更新日期：1988-01-01 00:00:00

abstract：BACKGROUND:The objective of this study was to evaluate the efficacy and safety of concurrent immune checkpoint inhibitor therapy and radiotherapy (immunoradiotherapy) in patients with metastatic melanoma after progression on nivolumab. PATIENTS AND METHODS:A retrospective review was performed on 16 consecutive patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Nomura M,Otsuka A,Yoshimura M,Nonomura Y,Kaku Y,Matsumoto S,Muto M

更新日期：2018-05-01 00:00:00

abstract：:Thirty-five patients with a diagnosis of non-Hodgkin's lymphoma of low histological grade were treated with 2 X 10(6)/m2 of human rDNA alpha 2 IFN-a2 by subcutaneous injection. Treatment was continued until progressive disease was documented or one year of therapy had been given. None of the patients had to stop treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Wagstaff J,Loynds P,Crowther D

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas. The goal of the study was to define the maximum tolerated dose (MTD) and to characterize the pharmacokinetics of gefitinib when combined with temozolomide. PATIENTS AND METHODS:Patients were stratified according to ...

journal_title：Cancer chemotherapy and pharmacology

authors： Prados MD,Yung WK,Wen PY,Junck L,Cloughesy T,Fink K,Chang S,Robins HI,Dancey J,Kuhn J

更新日期：2008-05-01 00:00:00

abstract：PURPOSE:Based on our mouse xenograft model demonstrating that intermittent high-dose gefitinib sensitizes tumors to subsequent treatment with taxanes, we initiated this phase I trial to explore docetaxel in combination with escalating doses of intermittent gefitinib (Iressa) given prior to docetaxel. METHODS:This was ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fury MG,Solit DB,Su YB,Rosen N,Sirotnak FM,Smith RP,Azzoli CG,Gomez JE,Miller VA,Kris MG,Pizzo BA,Henry R,Pfister DG,Rizvi NA

更新日期：2007-03-01 00:00:00

abstract：PURPOSE:The established treatment for small-cell lung cancer has been a cisplatin-etoposide combination, as the most effective chemotherapy regimen. Paclitaxel has also been used in combination with cisplatin and etoposide but this has been unacceptable due to the toxicity. This toxicity could be attributed to the thre...

journal_title：Cancer chemotherapy and pharmacology

authors： Stathopoulos GP,Trafalis D,Dimitroulis J,Kosmas Ch,Stathopoulos J,Tsavdaridis D

更新日期：2013-02-01 00:00:00

abstract：PURPOSE:Many cell lines resistant to cisplatin (DDP) have reduced DDP accumulation. We postulated that reduced accumulation of DDP in resistant cells might be due to decreased intracellular DDP binding, leading to increased passive efflux. METHODS:The total cellular ([T-DDP]), intracellular ultrafiltrable ([F-DDP]) an...

journal_title：Cancer chemotherapy and pharmacology

authors： Chau Q,Stewart DJ

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer. METHODS:A total...

journal_title：Cancer chemotherapy and pharmacology

authors： Pilancı KN,Saglam S,Okyar A,Yucel S,Pala-Kara Z,Ordu C,Namal E,Ciftci R,Iner-Koksal U,Kaytan-Saglam E

更新日期：2016-07-01 00:00:00

abstract：:MKT-077 (1-ethyl-2-[[3-ethyl-5-(3-methylbenzothiazolin-2-yliden)]-4- oxothiazolidin-2-ylidenemethyl] pyridinium chloride), a novel rhodacyanine dye in phase I/II clinical trials, may provide a new approach to cancer therapy based on the accumulation in the mitochondria of the cells of certain carcinomas, for example, ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tatsuta N,Suzuki N,Mochizuki T,Koya K,Kawakami M,Shishido T,Motoji N,Kuroiwa H,Shigematsu A,Chen LB

更新日期：1999-01-01 00:00:00

abstract：:The cytotoxic effects of ketoconazole, an antifungal agent known to have some activity against human prostate cancer, adrenal cancer, and male metastatic breast cancer, were evaluated using colony-growth and clonogenic assays in eight malignant cell lines. The cytotoxicity of ketoconazole showed a dose- and time-depen...

journal_title：Cancer chemotherapy and pharmacology

authors： Rochlitz CF,Damon LE,Russi MB,Geddes A,Cadman EC

更新日期：1988-01-01 00:00:00

abstract：:Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC)...

journal_title：Cancer chemotherapy and pharmacology

authors： Chatelut E,Chevreau C,Brunner V,Martinez M,Houin G,Bugat R,Canal P

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. METHODS:Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10...

journal_title：Cancer chemotherapy and pharmacology

authors： Friedman HS,Keir ST,Houghton PJ,Lawless AA,Bigner DD,Waters SJ

更新日期：2001-11-01 00:00:00

abstract：PURPOSE:Ibrutinib is an orally administered, irreversible Bruton's tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. METHODS:Part 1 used an open-label, two-...

journal_title：Cancer chemotherapy and pharmacology

authors： de Jong J,Hellemans P,Jiao JJ,Huang Y,Mesens S,Sukbuntherng J,Ouellet D

更新日期：2017-12-01 00:00:00

abstract：:Forty-one previously treated patients with advanced Hodgkin's disease were treated with a combination chemotherapy regimen -- ABVD (adriamycin, bleomycin, velbe/vincristine, imidazole carboxamide). Complete remission was achieved in three patients (7%), partial remission in 23 (56%), and no response in 15 patients (37...

journal_title：Cancer chemotherapy and pharmacology

authors： Sutcliffe SB,Wrigley PF,Stansfeld AG,Malpas JS

更新日期：1979-01-01 00:00:00